Restricted accessResearch articleFirst published online 2024-12
Maintenance of Long-Term Effective Humoral Immune Response in Patients with COVID-19 with Homologous or Heterologous Booster Vaccines: A Retrospective Study
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and first identified in Wuhan, China, in December 2019, has led to global efforts in vaccination to mitigate rising morbidity and mortality, with vaccines proving crucial in controlling the pandemic. This study evaluated the humoral responses to the inactivated virus vaccine Sinopharm or Koxing Kerlafor, the protein subunit vaccine ZF001, and the adenoviral vector vaccine Convidecia after 18 months of inactivated virus vaccination by heterologous and homologous booster vaccination in patients with previous SARS-CoV-2 infection and healthy individuals. We discovered that patients who had recovered from the infection and then received a third vaccine dose (booster) exhibited durable immunity. Furthermore, the heterologous booster vaccine induced higher neutralizing antibody responses compared with the homologous booster. These findings offer valuable insights into the efficacy of different COVID-19 vaccine strategies following booster immunization.
Get full access to this article
View all access options for this article.
References
1.
AmannaIJ, SlifkaMK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev, 2010; 236(1):125–138; doi: 10.1111/j.1600-065X.2010.00912.x
2.
BronskyJ, CopovaI, DurilovaM, et al.Postvaccination immunogenicity of BNT162b2 SARS-CoV-2 vaccine and its predictors in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr, 2023; 76(2):e36–e44; doi: 10.1097/MPG.0000000000003661
3.
BruelT, PinaudL, TondeurL, et al.Neutralising antibody responses to SARS-CoV-2 Omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study. EClinicalMedicine, 2022; 51:101576; doi: 10.1016/j.eclinm.2022.101576
4.
CaoY, HaoX, WangX, et al.Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine. Cell Res, 2022; 32(1):107–109; doi: 10.1038/s41422-021-00596-5
5.
China NHC of the PR of and Medicine NA of TC. Translation: Diagnosis and treatment protocol for COVID-19 (Revised Trial Version 8). Infect Microbes Dis, 2022; 4(3):85; doi: 10.1097/IM9.0000000000000094
6.
Costa ClemensSA, WeckxL, ClemensR, et al.RHH-001 study team. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): A phase 4, non-inferiority, single blind, randomised study. Lancet, 2022; 399(10324):521–529; doi: 10.1016/S0140-6736(22)00094-0
7.
EarleKA, AmbrosinoDM, Fiore-GartlandA, et al.Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine, 2021; 39(32):4423–4428; doi: 10.1016/j.vaccine.2021.05.063
8.
ErdemMG, UnluO, BuberS, et al.Could Prior COVID-19 affect the neutralizing antibody after the third BNT162b2 booster dose: A longitudinal study. Vaccines (Basel), 2023; 11(3):560; doi: 10.3390/vaccines11030560
9.
EybpooshS, BiglariA, SorouriR, et al.Immunogenicity and safety of heterologous boost immunization with PastoCovac plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals. PLoS Pathog, 2023; 19(11):e1011744; doi: 10.1371/journal.ppat.1011744
10.
FarahmandB, LarijaniMS, FotouhiF, et al.Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine. Heliyon, 2023; 9(10):e20555; doi: 10.1016/j.heliyon.2023.e20555
11.
FathiM, VakiliK, SayehmiriF, et al.The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study. PLoS One, 2021; 16(2):e0246190; doi: 10.1371/journal.pone.0246190
12.
GaoB, HeL, BaoY, et al.Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against omicron variants in breakthrough infection. Cell Res, 2023; 33(3):258–261; doi: 10.1038/s41422-023-00781-8
13.
GuoJ, LiL, WuQ, et al.Detection and predictors of anti-SARS-CoV-2 antibody levels in COVID-19 Patients at 8 months after symptom onset. Future Virol, 2021; 0(0); doi: 10.2217/fvl-2021-0141
14.
HeZ, RenL, YangJ, et al.Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: A longitudinal, population-level, cross-sectional study. Lancet, 2021; 397(10279):1075–1084; doi: 10.1016/S0140-6736(21)00238-5
15.
JaraA, UndurragaEA, ZubizarretaJR, et al.Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: A large-scale prospective cohort study. Lancet Glob Health, 2022; 10(6):e798–e806; doi: 10.1016/S2214-109X(22)00112-7
16.
JiangF, DengL, ZhangL, et al.Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med, 2020; 35(5):1545–1549; doi: 10.1007/s11606-020-05762-w
17.
JinP, GuoX, ChenW, et al.Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 Vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. PLoS Med, 2022; 19(5):e1003953; doi: 10.1371/journal.pmed.1003953
18.
KaabiNA, YangYK, ZhangJ, et al.Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: A Phase 2 Trial. Signal Transduct Target Ther, 2022; 7(1):172; doi: 10.1038/s41392-022-00984-2
19.
LiC, BiH, FuZ, et al.Precise-CoVaccine study group. Retrospective study of the immunogenicity and safety of the CoronaVac SARS-CoV-2 vaccine in people with underlying medical conditions. Commun Med (Lond), 2022a;2(1):151; doi: 10.1038/s43856-022-00216-2
20.
LiJ, HouL, GuoX, et al.Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: A randomized phase 4 trial. Nat Med, 2022b;28(2):401–409; doi: 10.1038/s41591-021-01677-z
21.
MallapatyS. China’s COVID vaccines have been crucial - now immunity is waning. Nature, 2021; 598(7881):398–399; doi: 10.1038/d41586-021-02796-w
22.
Meijide MíguezH, Montes GarcíaI, Ochando GómezM, et al.Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: A real-life study. Rev Esp Geriatr Gerontol, 2023; 58(3):125–133; doi: 10.1016/j.regg.2023.02.009
23.
NaaberP, TserelL, KangroK, et al.Declined antibody responses to COVID-19 mRNA vaccine within first three months. medRxiv, 2021; doi: 10.1101/2021.04.19.21255714
24.
RamezaniA, SorouriR, Haji MaghsoudiS, et al.PastoCovac and PastoCovac plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals. Sci Rep, 2023; 13(1):8065; doi: 10.1038/s41598-023-35147-y
25.
ThonV, PilerP, PavlíkT, et al.Investigation of SARS-CoV-2 seroprevalence in relation to natural infection and vaccination between October 2020 and September 2021 in the Czech Republic: A prospective national cohort study. BMJ Open, 2023; 13(3):e068258; doi: 10.1136/bmjopen-2022-068258
26.
TworekA, JarońK, CichaM, et al.The persistence of SARS-CoV-2 neutralizing antibodies after COVID-19: A one-year observation. Is a SARS-CoV-2 vaccination booster dose necessary? Cent Eur J Immunol, 2023; 48(2):92–96; doi: 10.5114/ceji.2023.126206
27.
WangY, ZhangL, SangL, et al.Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest, 2020; 130(10):5235–5244; doi: 10.1172/JCI138759
28.
WangZ, ZhaoZ, CuiT, et al.Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants. Emerg Microbes Infect, 2022; 11(1):829–840; doi: 10.1080/22221751.2022.2048969
29.
YangS, LiY, DaiL, et al.Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, Phase 1 and 2 Trials. Lancet Infect Dis, 2021; 21(8):1107–1119; doi: 10.1016/S1473-3099(21)00127-4
30.
YuJ, HuaF, QinD, et al.Impact of citywide COVID-19 testing on people’s behaviour in seeking for dental services in Wuhan. Oral Dis, 2022; 28(Suppl 1):922–924; doi: 10.1111/odi.13613
31.
ZhangX, ZhangW, ChenS. Shanghai’s life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet, 2022; 399(10340):2011–2012; doi: 10.1016/S0140-6736(22)00838-8
32.
ZhaoX, ZhengA, LiD, et al.Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants. Lancet Microbe, 2021; 2(10):e494; doi: 10.1016/S2666-5247(21)00217-2
33.
ZuoF, AbolhassaniH, DuL, et al.Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 omicron variant. Nat Commun, 2022; 13(1):2670; doi: 10.1038/s41467-022-30340-5
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
